The FDA has issued tentative marketing approval for Sun Pharmaceutical Industries' duloxetine hydrochloride, a copy of Eli Lilly and Co.'s Cymbalta. The drug is used for treating generalized anxiety disorder, diabetic peripheral neuropathic pain and major depressive disorder. Sun will launch the generic product in 20-, 30- and 60-milligram capsules.

Related Summaries